[Letter to the Editor] Genetic Control
By Marcy Darnovsky,
The New Yorker
| 12. 14. 2015
Specter highlights exciting developments in the field of gene editing, but he is too quick to dismiss the shadow side. Writing that CRISPR “offers a new outlet for the inchoate fear of tinkering with the fundamentals of life” is an inadequate characterization of the risks involved. The piece describes a nightmare of Jennifer Doudna’s, in which she tutors Hitler about editing genes, but does not reference Eric Lander’s sober warning, in an article on heritable genome manipulation, in the New England Journal of Medicine. Specter does not mention that dozens of countries, including most with developed biotech sectors, have written prohibitions on heritable genetic manipulation into their laws, and into a binding international treaty. In distinguishing the public—and its advocates—from scientists, Specter might lead readers to erroneously believe that researchers are not deeply concerned. Nearly all scientists want a broad public debate about what kind of gene editing should be pursued. This is a potentially society-altering technology, and democratic engagement with its trajectory is crucial and pressing.
Marcy Darnovsky
Executive Director, Center for Genetics and Society
Berkeley, Calif.
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...